News & Press Releases - 2018

November 28, 2018

Incysus Therapeutics Announces Presentations at 2018 ASH and HAPLO Annual Meetings

Incysus Therapeutics, Inc. announced that data related to the Company’s ongoing programs will be presented at the 60th American Society of Hematology Annual Meeting & Exposition (ASH) and at the 6th annual Haploidentical Transplant Symposium (HAPLO2018) this week in San Diego, CA. 

November 15, 2018

Gamma-Delta (γδ) T Cell Therapy Combined with Checkpoint Inhibition Shows Potential Synergies In Vitro for Treatment of Glioblastoma

Incysus Therapeutics, Inc. announced that Lawerence S. Lamb, PhD, a Scientific Co-Founder of Incysus will present a poster during the 23rd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) in New Orleans. The preclinical data demonstrates that Incysus' technology using gene-modified γδ T cells, in combination with checkpoint inhibitor antibodies has the potential to drive synergies to increase immune mediated killing of glioblastoma.  

October 22, 2018

Incysus Therapeutics to Participate in Panel at the 2018 Life Sciences Summit

Incysus Therapeutics, Inc. announced that William Ho, President and Chief Executive Officer will join a distinguished group of panelists including representatives from Merck, Bristol-Myers Squibb, Quentis Therapeutics and Memorial Sloan-Kettering Cancer Center during the “Therapeutic Insight: Immuno-Oncology’s Next Generation Therapies” panel at the 2018 Life Sciences Summit

October 16, 2018

Incysus Therapeutics to Present at the 2018 BIO Investor Forum

Incysus Therapeutics, Inc. announced that William Ho, a Co-Founder of Incysus, President and CEO will present a company overview at the annual BIO Investor Forum conference being held in San Francisco.  The presentation will be on Thursday, October 18, 2018 at 10:15am PDT in the Elizabethan A room at the Westin St. Francis Hotel.

August 16, 2018

Lawrence Lamb, Ph.D. Incysus Therapeutics Scientific Co-Founder to Present at 10th Annual Bioprocessing Summit

Incysus Therapeutics, Inc. announced that Lawrence Lamb, PhD, a Scientific Co-Founder of Incysus, will present at a scientific symposium today, on Thursday, August 16, 2018 during the 10th Annual Bioprocessing Summit, in Boston, Massachusetts.  The discussion will focus on the scale-up and GMP manufacturing of gene-modified γδ T cells for a Phase I trial.

June 8, 2018

Incysus Therapeutics Scientific Co-Founder Lawrence Lamb, PhD to Present at 8th International Gamma-Delta T Cell Conference

Incysus Therapeutics, Inc. announced that Lawrence Lamb, PhD, a Scientific Co-Founder of Incysus, will present at a scientific symposium on June 10, 2018 during the 8th International Gamma-Delta T Cell Conference, in Bordeaux, France.  Dr. Lamb's session is titled: “Targeting of chemotherapy-induced NKG2DL by localized repetitive γδ T cell infusions: a rational therapeutic design for elimination of minimal residual primary high grade gliomas”.

May 22, 2018

Incysus Moves Its Corporate Domicile to Delaware

Incysus, Ltd. announced that effective May 7, 2018 it had moved its corporate domicile from Bermuda to the United States of America in the State of Delaware.  Advancing ahead, the corporate name will now be Incysus Therapeutics, Inc.  Management expects that these changes will help support our growth strategy without affecting the day-to-day business and operations of the organization.

May 16, 2018

Incysus Therapeutics' Scientific Co-Founder Lawrence Lamb, PhD and Marcela Maus, MD, PhD to Co-Chair Gene Therapy Symposium During 2018 ASGCT Meeting

Dr. Lamb and Dr. Maus will Co-Chair a Symposium Titled: "Tipping Point: Gene Therapy Entering the Market” on Friday, May 18, 2018 at 8:00am CDT at the American Society of Gene and Cell Therapy (ASGCT) Meeting in Chicago.  Dr. Bruce Levine, PhD, also member of Incysus' Scientific Advisory Board will also present during the session.

May 14, 2018

Incysus Announces Appointment of Joy Bessenger as Senior Vice President, Finance and Strategy

Joy E. Bessenger has been appointed Senior Vice President, Finance and Strategy to help Incysus advance through its next stage of growth as it prepares to initiate clinical programs in 2018

March 21, 2018

Incysus to Present at BioCentury Future Leaders Conference

William Ho, Chief Executive Officer of Incysus will present at the 25th Annual BioCentury Future Leaders Conference on Friday, March 23, 2018 at 2:30pm EDT at the Millennium Broadway Hotel and Conference Center in New York

March 20, 2018

Incysus to Present Scientific Overview at the 2018 CAR-T Congress USA Meeting

Dr. Lawrence Lamb, to Present Adoptive Gamma-Delta T cell Immunotharpy as a Strategy for Eliminating Residual Malignancy at CAR-T Congress USA Meeting in Boston

February 13, 2018

Incysus Presents Positive Data on Drug-Resistant Immunotherapy for Glioblastoma at AACR CNS Immunotherapy Conference

Dr. Lawrence Lamb, PhD to present at a Plenary Session of the Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy, a special AACR conference being held in San Diego, California

January 9, 2018

Incysus Submits Second Investigational New Drug Application for Gamma-Delta T Cell Immunotherapy Candidate

IND to support Phase 1 safety and activity study of Drug Resistant Immunotherapy for the treatment of glioblastoma.

©2020 by Incysus Therapeutics, Inc.  |  |  Privacy Policy  |  Terms of Use